Sotrovimab, a treatment from Vir Biotechnology and GlaxoSmithKline, is expected to remain effective against omicron.
With the omicron variant of the coronavirus poised to thwart most covid-19 treatments, U.S. public health officials are stockpiling the one monoclonal antibody that remains effective so that it can be deployed when the variant becomes more prevalent.
The decision to pause every-other-week shipments to states of the treatment, sotrovimab, shortly after Thanksgiving is part of a broader strategy to marshal the most effective tools to combat omicron, according to David Kessler, chief scientific officer of the White House covid-19 response team…
This tells you the feds knew that omicron would only respond to this monoclonal. But are they testing people for their specific variant before pushing the other monoclonals into their veins? No.